Regulation of human B cell function by sulfasalazine and its metabolites

被引:41
作者
Hirohata, S [1 ]
Ohshima, N [1 ]
Yanagida, T [1 ]
Aramaki, K [1 ]
机构
[1] Teikyo Univ, Sch Med, Dept Internal Med, Itabashi Ku, Tokyo 1738605, Japan
关键词
disease-modifying antirheumatic drugs; B cells; immunoglobulin; T cells; anti-CD3;
D O I
10.1016/S1567-5769(01)00186-2
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 [免疫学];
摘要
Although sulfasalazine is a well-known disease-modifying antirheumatic drug (DMARD), the mechanisms of its action remain unclear. Indeed, it remains uncertain whether sulfasalazine itself or one of its metabolites is responsible for the antirheumatic effects of sulfasalazine. Since one of the characteristic features of rheumatoid arthritis (RA) is chronic stimulation of B cells, we compared the effects of sulfasalazine and its metabolites on the in vitro function of human B cells. Ig production was induced from highly purified B cells from healthy donors by stimulation with Staphylococcus aureus Cowan I (SA) plus IL-2. Sulfasalazine suppressed the production of IgM and IgG at its pharmacologically attainable concentrations (1-10 mug/ml). Of the metabolites of sulfasalazine, sulfapyridine (SP) and 5-aminosalicylic acid (5-ASA), but not 4-acethyl SP, also significantly suppressed the production of IgM and IgG at their pharmacologically relevant concentrations. By contrast, any of sulfasalazine, SP, 5-ASA and 4-acethyl SP did not suppress the IFN-gamma production of immobilized anti-CD3 stimulated CD4+ T cells. These results indicate that sulfasalazine and its metabolites preferentially suppress the function of B cells, but not that of T cells, at their pharmacologically attainable concentrations. The data therefore suggest that not only sulfasalazine, but its metabolites, might contribute to the beneficial effects of sulfasalazine. (C) 2002 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:631 / 640
页数:10
相关论文
共 32 条
[1]
BANDTZAEG P, 1974, GASTROENTEROLOGY, V66, P1123
[2]
BAX DE, 1986, BRIT J RHEUMATOL, V25, P282
[3]
Bissonnette EY, 1996, J IMMUNOL, V156, P218
[4]
SUPPRESSION OF COLLAGEN-INDUCED ARTHRITIS BY COMBINATION CYCLOSPORINE-A AND METHOTREXATE THERAPY [J].
BRAHN, E ;
PEACOCK, DJ ;
BANQUERIGO, ML .
ARTHRITIS AND RHEUMATISM, 1991, 34 (10) :1282-1288
[5]
THE ABILITY OF SYNOVIOCYTES TO SUPPORT TERMINAL DIFFERENTIATION OF ACTIVATED B-CELLS MAY EXPLAIN PLASMA-CELL ACCUMULATION IN RHEUMATOID SYNOVIUM [J].
DECHANET, J ;
MERVILLE, P ;
DURAND, I ;
BANCHEREAU, J ;
MIOSSEC, P .
JOURNAL OF CLINICAL INVESTIGATION, 1995, 95 (02) :456-463
[6]
SULFASALAZINE IN ANKYLOSING-SPONDYLITIS - A DOUBLE-BLIND CONTROLLED-STUDY IN 60 PATIENTS [J].
DOUGADOS, M ;
BOUMIER, P ;
AMOR, B .
BRITISH MEDICAL JOURNAL, 1986, 293 (6552) :911-914
[7]
Gadangi P, 1996, J IMMUNOL, V156, P1937
[8]
GEPPERT TD, 1987, J IMMUNOL, V138, P1660
[9]
INHIBITION OF PROSTAGLANDIN SYNTHETASE IN HUMAN RECTAL MUCOSA [J].
HAWKEY, CJ ;
TRUELOVE, SC .
GUT, 1983, 24 (03) :213-217
[10]
MODULATION OF T-CELL PRODUCTION OF INTERFERON-GAMMA BY HUMAN MONOCYTES - EFFECT OF ENGAGEMENT OF CD14 ON MONOCYTES [J].
HIROHATA, S ;
OKA, H .
CELLULAR IMMUNOLOGY, 1993, 151 (02) :270-282